ストックスクリーナーアプリを入手
0.4076
3.53%
-0.0149
アフターアワーズ：
.42
0.0124
+3.04%
前日終値:
$0.4225
開ける：
$0.4224
24時間の取引高:
795.00K
Relative Volume:
0.22
時価総額：
$23.09M
収益：
-
当期純損益:
$-28.53M
株価収益率:
-0.2289
EPS:
-1.7805
ネットキャッシュフロー:
$-20.10M
1週間 パフォーマンス:
-2.09%
1か月 パフォーマンス:
+27.38%
6か月 パフォーマンス:
-73.70%
1年 パフォーマンス:
-87.65%
1日の値動き範囲:
$0.395
$0.435
1週間の範囲:
$0.395
$0.4715
52週間の値動き範囲:
$0.25
$3.35
Medicus Pharma Ltd Stock (MDCX) Company Profile
名前
Medicus Pharma Ltd
セクター
電話
610-540-7515
住所
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4076 | 23.09M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd (MDCX) 最新ニュース
Enterprise value to revenue forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Enterprise value to EBIT forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Price to sales forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - The Poughkeepsie Journal
MDCX Stock Price, Quote & Chart - ChartMill
MDCXMedicus Pharma Ltd Revenue Breakdown - Finviz
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group - guardonline.com
Medicus Pharma Warrants (MDCXW) Rally 4.6% as Buyers Defend SupportCall Resistance - dars.gov.et
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology? - Insider Monkey
Medicus Pharma Ltd Actuals & Estimates (NASDAQ:MDCX) - TradingView
MDCX Q1 2026 Earnings: Wider Than Expected Loss Reflects Pre-Revenue StageRevenue Surprise History - dars.gov.et
MDCX Forecast — Price Target — Prediction for 2027 - TradingView
Medicus Pharma on Bloomberg World - Montgomery Advertiser
Medicus Pharma Ltd (MDCXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd. (MDCX) Shows Modest Uptick Amid Consolidation at $0.46Sentiment Shift - dars.gov.et
Medicus Pharma Ltd Provides Updates on Skinject Phase 2B Pivotal Study and Teverelix Precision Medicine Program - marketscreener.com
Medicus Pharma to present SkinJect, Teverelix updates at BIO International 2026 - Proactive financial news
Medicus Pharma to Present Clinical and Regulatory Updates at 2026 Bio International Conference - Quiver Quantitative
Medicus brings SkinJect and Teverelix data to Bio 2026 - Stock Titan
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 - The Manila Times
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma advances Teverelix in prostate cancerICYMI - Proactive financial news
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy - MyChesCo
Medicus Pharma Ltd (MDCXW) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Montgomery Advertiser
This $9 SpaceX Stock Has Crazy Potential Geena Davis (jBXkEb6qgn) - Mshale
This $9 SpaceX Stock Has Crazy Potential Ottawa News (6IhxvTriSq) - Fathom Journal
Medicus advances Teverelix and SkinJect programs with key regulatory filings - Proactive financial news
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the United States Food and Drug Administration (FDA) seeking Rare Pediatric Disease Designation for its investigational product Skinject® for the indication of Gorlin syndrome. - Bitget
Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer - Proactive financial news
Small cap wrap: Medicus Pharma, First Phosphate, Standard Uranium... - Proactive financial news
Medicus Dips on FDA Nod - Baystreet.ca
Medicus Pharma seeks rare pediatric disease status for patch By Investing.com - Investing.com South Africa
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome - Proactive financial news
Medicus Pharma seeks rare pediatric disease status for patch - Investing.com
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma Ltd (MDCX) 財務データ
収益
当期純利益
現金流量
EPS
0.33%
1.23%
大文字化:
|
ボリューム (24 時間):